Navigation Links
Relmada Therapeutics Raises $3.0 Million In Initial Closing Of Series A Financing
Date:7/24/2012

BLUE BELL, Pa., July 24, 2012 /PRNewswire/ -- Relmada Therapeutics, a clinical-stage company developing novel therapies for the treatment of chronic pain today announced the initial closing of $3 million in gross proceeds in a Series A financing for which Laidlaw & Company (UK) Ltd. is the exclusive placement agent.  Noteholders BioAdvance and Ben Franklin Technology Partners of Southeastern Pennsylvania, as well as, equity investor Wonpung Mulsan Co., Ltd, have converted their existing liens into the Series A Convertible Preferred Stock.

The initial Series A proceeds will be used to continue the development of LevoCap, a proprietary once-a-day extended release dosage form of the potent opioid levorphanol in a tamper resistant delivery system and for general corporate activities. 

"This impressive response from new investors and existing stakeholders speaks to the potential of our diversified portfolio of drug candidates to address the significant unmet medical need in chronic pain," said Sergio Traversa, CEO of Relmada. "Based on this successful initial offering, we anticipate completing additional formulation development, GMP manufacturing and pharmacokinetic studies required to initiate Phase III studies by mid-2013.  The additional funds expected from the on-going Series A financing will be used to further develop our other products: MepiGel, d-methadone and BuTab," added Traversa.

Relmada's lead product, LevoCap is intended to add a new tool to treat chronic pain where non-opioids or other opioids do not provide adequate relief.  Unlike most other opioids, levorphanol, the active ingredient in LevoCap modulates pain through both opioid pathways and noradrenergic pathways, thereby providing pain relief through multiple mechanisms in a single molecule. Levorphanol has also been shown to partially reverse analgesic tolerance to morphine and may therefore benefit patients who are tolerant to the analgesic
'/>"/>

SOURCE Relmada Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
2. Nile Therapeutics Reports 2011 Third Quarter Financial Results
3. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
4. Fate Therapeutics Strengthens Its iPSC Platform
5. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
6. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
7. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
8. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
9. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
10. Aratana Therapeutics Completes $15 Million Series B Financing
11. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... -- Theravalues Corporation est fier d,annoncer le lancement ... salon Hi Europe 2014 (du 2 au 4 décembre ... Curcumine la plus biodisponible actuellement sur le marché, ... ingrédients approuvés par les règlements européens. ... la racine de curcuma ( Curcuma longa ) ...
(Date:11/26/2014)... -- Theravalues Corporation annuncia con orgoglio il lancio di ... Hi Europe 2014 (dal 2 al 4 dicembre, ... curcumina con la maggiore biodisponibilità di sempre, con una ... dalle norme europee. La curcumina è un ... Curcuma longa ) che è stata associata con attività ...
(Date:11/24/2014)... Nov. 24, 2014  IGI Laboratories, Inc. (NYSE MKT: ... specialty generic pharmaceutical company, today announced it has submitted ... U.S. Food and Drug Administration (FDA), which brings the ... seven, with eighteen submissions now pending at the FDA. ... CEO of the Company, commented, "Our team here at ...
(Date:11/24/2014)... 24, 2014  Last week, Representatives Gus ... (D-NC) took a bold bipartisan step on behalf ... OPEN Act. Original co-sponsors of the legislation include ... will incentivize drug makers and innovators to "repurpose" ... pediatric cancers, which opens the door to the ...
Breaking Biology Technology:La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 2La curcumine présentant la plus haute biodisponibilité bientôt en vente en Europe 3La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 2La curcumina con la maggiore biodisponibilità di sempre farà il suo debutto in Europa 3IGI Laboratories, Inc. Announces ANDA Submission 2OPEN Act Introduced to Repurpose Drugs for Rare Diseases 2
... 2009 , , ARVADA, Colo., June 16 ... and responsibility to our shareholders, is addressing our recent ... Finance 2009, a Biotechnology, Medical Devices, and world public ... 4-5. , , Pharma Finance is an international ...
... Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS ), a ... oncology therapeutics for the treatment of solid and hematologic cancers, ... will be presenting at the Jefferies 3rd Annual Healthcare Conference ... 17, 2009. , , The live webcast of this ...
... SHANGHAI, June 16 /PRNewswire-Asia/ -- Sundia MediTech Company, a,Shanghai-based ... facility in Shanghai has passed the audit from a ... are praised,for providing good facilities and programs for the ... The inspection and audit took place in May. ...
Cached Biology Technology:GeneThera Extends its Reach Overseas 2Sundia's Animal Facility Passed Client and Government Inspection 2
(Date:11/4/2014)... newly published research study examining only marketing directed ... fast food restaurants has found that the majority ... exposed to such marketing tactics. , Authored by ... colleagues, the study is the first to examine ... and exterior of fast food restaurants and its ...
(Date:11/4/2014)... VILNIUS, Lithuania , Nov. 4, 2014 /PRNewswire/ ... identification technologies, today announced that the latest version ... place in the Ongoing MINEX evaluation ... interoperability of fingerprint algorithms using the INCITS 378 ... a mandatory requirement in public tenders in ...
(Date:11/3/2014)... 2014  NeuroSigma ® , Inc. (NeuroSigma), a ... focused on commercialization of its non-invasive ... of neurological and neuropsychiatric disorders, announced today that ... a Notice of Allowance for Mexican Patent Application ... NeuroSigma and the Regents of the University of ...
Breaking Biology News(10 mins):Fast food marketing for children disproportionately affects certain communities 2Fast food marketing for children disproportionately affects certain communities 3Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3
... (UK) are to investigate how lethal viruses attack differently sized ... the door to new methods of pest control. The project, ... grain-infesting Indian meal moth ( Plodia interpunctella ) and a ... and sometimes not. Dr Steve Sait from the University ...
... Virginia Tech released today the results of a new rating ... the risk of concussions. One currently manufactured helmet received ... helmets received the very good "4-star" rating. ... first time researchers have provided the public with comparative test ...
... Palo Alto, CA Accurately calculating the amount of ... bringing products to our doorsteps is nearly impossible, but ... a commentary published online this week by Proceedings of ... Ken Caldeira and Steven Davis commend the work of ...
Cached Biology News:No safety in numbers for moths and butterflies 2Virginia Tech announces football helmet ratings for reducing concussion risk 2Virginia Tech announces football helmet ratings for reducing concussion risk 3Virginia Tech announces football helmet ratings for reducing concussion risk 4Consumption, carbon emissions and international trade 2
Lingo-1 (K-13)...
HIF-1 beta (ARNT1) Purified Anti-Mouse, Anti-Rat, Anti-Human clone 29, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
MOUSE ANTI PORCINE SLA 1:FITC Immunogen: Porcine peripheral blood mononuclear cells....
An excellent carbonyl-reactive FRET quencher paired with Trp or Tyr. Minimum Purity: 95%. Abs(max): ~350 nm; Em(max): none. Solvent System:DMSO or DMF....
Biology Products: